Recent Updates
Recently added Catalysts
LNSR Positive Sentiment

LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day

Key Takeaway: LENSAR, Inc. will participate in the BTIG 4th Annual Ophthalmology Day on December 2, 2024. CEO Nick Curtis will engage in a fireside chat during the event, which is exclusive to BTIG clients. LENSAR is recognized for its advanced robotic laser solutions for cataract treatment, particularly with its ALLY Robotic Cataract Laser System that leverages AI and advanced imaging technologies for enhanced surgical efficiency.
Price reaction · baseline $7.36 (2024-11-25 close) · hit after-hours · clean, no other LNSR news in the window
day 0 close
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • LENSAR is participating in a reputable industry event, demonstrating ongoing engagement.
  • The new ALLY Robotic Cataract Laser System shows innovation and advanced technology in cataract treatment.
  • LENSAR's focus on AI integration into their devices indicates a forward-thinking approach for improved surgical outcomes.

Full Press Release Details

ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host 1-on-1 meetings with institutional investors.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.
Contacts: Lee Roth / Cameron Radinovic
Thomas R. Staab, II, CFO Burns McClellan for LENSAR
ir.contact@lensar.com lroth@burnsmc.com / cradinovic@burnsmc.com

Frequently Asked Questions

When will Nick Curtis speak at the BTIG Ophthalmology Day?

Nick Curtis will participate in the BTIG 4th Annual Ophthalmology Day on December 2, 2024, at 2 p.m. ET.

What is LENSAR focused on developing?

LENSAR focuses on advanced robotic laser solutions for cataract treatment and astigmatism management.

What technology does the ALLY system utilize?

The ALLY Robotic Cataract Laser System™ uses a fast dual-modality laser with AI integration.

What does Streamline® technology do?

Streamline® software technology guides surgeons in achieving improved surgical outcomes.

Who can attend BTIG hosted events?

BTIG hosted events are for prospective and existing BTIG clients only.

Last updated: Nov 26, 2024